Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 17/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 17/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 17/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.86 |
| ▸ | LCK | P06239 | 1/20 | 0.86 |
| ▸ | FYN | P06241 | 1/20 | 0.86 |
| ▸ | CSF1R | P07333 | 1/20 | 0.86 |
| ▸ | YES1 | P07947 | 1/20 | 0.86 |
| ▸ | LYN | P07948 | 1/20 | 0.86 |
| ▸ | HCK | P08631 | 1/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.86 |
| ▸ | ROS1 | P08922 | 1/20 | 0.86 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.86 |
| ▸ | FGR | P09769 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | SRC | P12931 | 1/20 | 0.86 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.86 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.86 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neflamapimod SCHEMBL156367 | 0.93 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| Neflamapimod SCHEMBL29396525 | 0.93 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139590 | 0.91 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL20885633 | 0.91 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139595 | 0.87 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL19892655 | 0.86 | MAPK14 (0.87) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139569 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139555 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL5635285 | 0.85 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139614 | 0.85 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338412-B2 | Inhibitors of P38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338412-B2 | Inhibitors of P38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110281878-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281878-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | US | disclosed |
| US-7951809-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951809-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090203702-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203702-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-13 | — | — | US | disclosed |
| US-7365072-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365072-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-29 | — | — | US | disclosed |
| US-7205305-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205305-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281878-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | MAPK14 46/4885MAPK13 53/4885MAPK12 24/4885 |
| US-20090203702-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | MAPK14 46/4885MAPK13 53/4885MAPK12 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.